争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 2 条
2020
Stafford家属因Vivitrol对Alkermes提起过失致死诉讼
提起诉讼
一名因阿片类药物过量死亡的男子的父母对Alkermes提起过失致死诉讼。诉讼指称Alkermes未警告患者停用Vivitrol后复吸的过量风险，并称该药无效且营销具有欺骗性。Alkermes表示坚信Vivitrol的疗效与安全性，并将积极应诉。
一名因阿片类药物过量死亡的男子的父母起诉Alkermes。诉讼指称Alkermes未警告患者停用Vivitrol后复吸的过量风险，并称该药无效且营销具有欺骗性。Alkermes表示坚信Vivitrol的疗效与安全性，并将积极应诉。
品牌回应
否认 — Alkermes
The company said in a statement that it stands by "the efficacy and safety of Vivitrol and will vigorously defend the matter.
来源摘录
The parents of a 26-year-old California man who died of an opioid overdose have sued the Waltham manufacturer of Vivitrol, the medication he took to treat his addiction, in a case that highlights the controversies surrounding the response to the nationâs opioid crisis.
Adam H. Weintraub, one of plaintiffsâ attorneys, said that as far as he knows this suit, filed in Superior Court in Los Angeles Jan. 31, is the first personal-injury lawsuit involving Vivitrol, the newest of three medications to treat opioid addiction.
The wrongful-death suit alleges Alkermes failed to warn of the high risk of overdose when patients stop taking Vivitrol and then relapse into opioid use. It also claims Vivitrol is ineffective and deceptively marketed.
2019
Vivitrol营销和解案
美国司法部宣布，Alkermes同意支付1.25亿美元，以了结涉及Vivitrol营销的指控。相关指控包括为该产品推广未经其获批标签支持的用途或使用方式。该和解协议不包含公司承认责任的内容。